Metallus (NYSE:MTUS) Stock

Metallus

TimkenSteel

Metallus Inc is an America-based manufacturer of alloy steel, as well as carbon and micro-alloy steel. The portfolio of the company includes special bar quality steel, seamless mechanical tubes, and value-add solutions, such as precision steel components. The company also supplies machining and thermal treatment services and manages raw material recycling programs that work as a feeder system for its melt operations. The company's products and services are used in the following sectors: oil and gas; automotive; industrial equipment; mining; construction; rail; aerospace and defense; heavy truck; agriculture and power generation. Geographically, the company mainly serves customers in the United States.

Metallus Inc

Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors
Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors
Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage
Twist remains focused on serving customers across the life sciences spectrum and expanding revenue and gross margin while driving toward adjusted EBITDA breakeven, now expected by the end of fiscal 2026
Twist to retain minority ownership in Atlas Data Storage
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.twistbioscience.com%2F&amp;esheet=54248406&amp;newsitemid=20250505213784&amp;lan=en-US&amp;anchor=Twist+Bioscience+Corporation&amp;index=1&amp;md5=ab4c0cc27c1052499c1fbf60a4b0e1e7">Twist Bioscience Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that the company has spun out its DNA data storage technology application as an independent company, named Atlas Data Storage ("Atlas").
Under the terms of the contribution and license agreements, Twist assigned and licensed its DNA data storage technology to Atlas in exchange for Twist receiving a minority ownership interest upon close, an upfront cash payment and a secured promissory note. Twist retains an ownership stake in Atlas and may participate in the upside of DNA data storage through future technology and commercial milestone payments, and a revenue share through royalties on future sales of Atlas' products and services. In addition, Twist will benefit from technology advancements made by Atlas where it applies to Twist's product groups.
 &nbsp;

News

TWST

Twist Bioscience Spins Out DNA Data Storage Technology Application As Independent Company, Named Atlas Data Storage

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(1.33) by 48.87 percent. This is a 32 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $121.46 million which beat the analyst consensus estimate of $119.87 million by 1.33 percent. This is a 61.95 percent increase over sales of $75.00 million the same period last year.

Earnings

Earnings Beats

AXSM

Axsome Therapeutics Q1 Adj. EPS $(0.68) Beats $(1.33) Estimate, Sales $121.46M Beat $119.87M Estimate

BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported quarterly sales of $145.53 million which beat the analyst consensus estimate of $126.87 million by 14.71 percent. This is a 56.89 percent increase over sales of $92.76 million the same period last year.

BCRX

BioCryst Pharma Q1 Sales $145.53M Beat $126.87M Estimate

Telsey Advisory Group analyst Sarang Vora maintains Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) with a Outperform and maintains $52 price target.

Price Target

Analyst Ratings

VITL

Telsey Advisory Group Maintains Outperform on Vital Farms, Maintains $52 Price Target

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is looking for Q2 Adj EPS of $0.41-$0.44 vs $0.43 analyst estimate. sees sales of $19.700 million-$19.900 million vs $19.81 million analyst estimate.

Guidance

IRMD

iRadimed Sees Q2 Adj EPS $0.41-$0.44 vs $0.43 Est; Sees Sales $19.700M-$19.900M vs $19.81M Est

Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) today announced revised subscription rights in connection with its previously announced rights offering.
Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025.
Under the proposed rights offering, Rafael Holdings intends to distribute one (1) non-transferable subscription right for each share of Class B Common Stock or Class A Common Stock or share of Class B Common Stock purchasable on exercise of Public Warrants, in each case, held as of the Record Date. Each subscription right will entitle the Holder to purchase 0.603 of a share of Class B Common Stock at a subscription price of $1.28 per share. Subscription rights may only be exercised in whole numbers, and fractional shares will not be issued. The number of shares that may be purchased by each holder of subscription rights will be rounded down to the nearest whole number.
 &nbsp;

Rafael Holdings Revises Subscription Rights Following Prior $25M Rights Offering To Support Development And Potential Launch Of Trappsol Cyclo

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) affirms FY2025 GAAP EPS guidance from $1.55-$1.65 to $1.55-$1.65 vs $1.64 analyst estimate..

iRadimed Affirms FY2025 GAAP EPS Guidance of $1.55-$1.65 vs $1.64 Est

HC Wainwright &amp; Co. analyst Yi Chen reiterates Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) with a Buy and maintains $50 price target.

Reiteration

TRML

HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $50 Price Target

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is looking for Q2 GAAP EPS of $0.37-$0.40 vs $0.41 analyst estimate..

iRadimed Sees Q2 GAAP EPS $0.37-$0.40 vs $0.41 Est

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) affirms FY2025 Adj EPS guidance from $1.71-$1.81 to $1.71-$1.81 vs $1.75 analyst estimate. Affirms FY2025 sales outlook from $78.00 million-$82.00 million to $78.00 million-$82.00 million vs $79.41 million estimate.

iRadimed Affirms FY2025 Adj EPS Guidance of $1.71-$1.81 vs $1.75 Est; Affirms FY2025 Sales Guidance of $78.00M-$82.00M vs $79.41M Est

Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) with a Market Perform and lowers the price target from $7 to $5.

FIGS

Telsey Advisory Group Maintains Market Perform on FIGS, Lowers Price Target to $5

<ul>
<li>MaGic trial exceeded enrollment target of 60 patients</li>
<li>Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26</li>
<li>Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential&nbsp;best-in-class, potent classical pathway inhibitor intended as a self-administered&nbsp;autoinjector dosed once every two weeks</li>
</ul>

DNTH

Dianthus Completes Enrollment In Phase 2 MaGic Trial Of DNTH103 For gMG, Top-Line Results Expected September

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

Needham analyst Laura Martin maintains FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) with a Buy and lowers the price target from $3.35 to $3.

FUBO

Needham Maintains Buy on FuboTV, Lowers Price Target to $3

Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) ("Sunoco" or the "Partnership") and Parkland Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PKI#TSX">PKI</a>) ("Parkland") announced today that the parties have entered into a definitive agreement whereby Sunoco will acquire all outstanding shares of Parkland in a cash and equity transaction valued at approximately $9.1 billion, including assumed debt. &nbsp;
&nbsp;
As part of the transaction, Sunoco intends to form a new publicly-traded Delaware limited liability company named SUNCorp, LLC ("SUNCorp"). SUNCorp will hold limited partnership units of Sunoco that are economically equivalent to Sunoco's publicly-traded common units on the basis of one Sunoco common unit for each outstanding SUNCorp unit.&nbsp;This new publicly-traded entity will be treated as a corporation for tax purposes. For a period of two years following closing of the transaction, Sunoco will ensure that SUNCorp unitholders will receive the same dividend equivalent as the distribution to Sunoco unitholders.
Transaction Details
Under the terms of the agreement, Parkland shareholders will receive 0.295 SUNCorp units and C$19.80 for each Parkland share, implying a 25% premium based on the 7-day VWAP's of both Parkland and Sunoco as of May 2, 2025. Parkland shareholders can elect, in the alternative, to receive C$44.00 per Parkland share in cash or 0.536 SUNCorp units for each Parkland share, subject to proration to ensure that the aggregate consideration payable in connection with the transaction does not exceed C$19.80 in cash per Parkland share outstanding as of immediately before close and 0.295 SUNCorp units per Parkland share outstanding as of immediately before close.
Sunoco has secured a $2.65 billion 364-day bridge term loan for the proposed cash consideration.
The transaction has been unanimously approved by the board of directors of both companies and is expected to close in the second half of 2025 upon the satisfaction of closing conditions, including approval by Parkland's shareholders and customary regulatory and stock exchange listing approvals.

TSX:PKI

Sunoco to Acquire Parkland Corporation in $9.1B Cash and Equity Deal

RIME

Algorhythm's Subsidiary Announced The Acquisition Of 9,999 Of The 10,000 Issued And Outstanding Equity Shares Of Semicab India In Exchange Of A $1.75M Promissory Note And 119,742 Shares Of Its Common Stock

Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 35.71 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $10.70 million which missed the analyst consensus estimate of $16.83 million by 36.44 percent. This is a 27.59 percent decrease over sales of $14.77 million the same period last year.

Earnings Misses

OCUL

Ocular Therapeutix Q1 EPS $(0.38) Misses $(0.29) Estimate, Sales $10.70M Miss $16.83M Estimate

Stanford-led study included over 2,100 Signatera samples from over 200 sarcoma patients, with overall sensitivity of 89% and specificity of 100%
Leiomyosarcoma, the most common subtype in the cohort, demonstrated sensitivity of 93% and specificity of 100%

NTRA

Natera's Signatera Shows 93% Sensitivity In Leiomyosarcoma, Most Common Sarcoma Subtype In Study

Demonstrated Dose Dependent Effect in EAU
Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting
PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) today announced preclinical data on the use of Purified Cortrophin&#xAE; Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model.
"In a preclinical model of autoimmune uveitis, Cortrophin Gel reduced levels of inflammatory molecules without stimulating an adverse immune response," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "The results further support our understanding of Cortrophin Gel's mechanism of action."
An experimental autoimmune uveitis (EAU) mouse model was used to determine the impact of four doses (4, 40, 160 or 400 U/kg) of repository corticotrophin injection (RCI, an equivalent to Cortrophin Gel in this model). The results showed a significant dose-dependent effect on the suppression of EAU at all doses, with the greatest suppression of EAU at the 400 U/kg dose. RCI also significantly suppressed the production of cytokines implicated in inflammation and immune system activation. Additionally, 400 U/kg Purified Cortrophin Gel treatment suppressed retinal damage caused by EAU, similar to α-MSH treatment, compared to placebo.
"The data presentation at ARVO is part of ANI's broader commitment to clinical research for our products and, specific to Cortrophin Gel, we are committed to building on the scientific evidence and clinical data supporting its mechanism of action and clinical use," said Nikhil Lalwani, President and Chief Executive Officer at ANI.

Biotech

General

ANIP

ANI Pharmaceuticals Announces Presentation Of Preclinical Data On Use Of Purified Cortrophin Gel In An Experimental Autoimmune Uveitis Mouse Model

Telsey Advisory Group analyst Dana Telsey maintains Zevia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZVIA#NYSE">ZVIA</a>) with a Market Perform and maintains $3 price target.

ZVIA

Telsey Advisory Group Maintains Market Perform on Zevia, Maintains $3 Price Target

Press Releases

Metallus Announces Second-Quarter 2024 Results

REMINDER: Metallus Announces Second-Quarter 2024 Earnings Webcast Details

Metallus Honored with 2024 NorthCoast 99 Award

Metallus Announces Third-Quarter 2024 Earnings Webcast Details

Metallus Announces Third-Quarter 2024 Results

REMINDER: Metallus Announces Third-Quarter 2024 Earnings Webcast Details

Metallus Announces Fourth-Quarter and Full-Year 2024 Earnings Webcast Details

Metallus Announces Fourth-Quarter and Full-Year 2024 Results

REMINDER: Metallus Announces Fourth-Quarter and Full-Year 2024 Earnings Webcast Details

Metallus Announces First-Quarter 2025 Earnings Webcast Details

MTUS

Ascent Industries

Alpha Metallurgical Resources, Inc. Common Stock

Alpha Metallurgical

Cleveland-Cliffs

Commercial Metals

Carpenter Technology Corporation Common Stock

Carpenter Tech

Friedman Indus

Gerdau

Warrior Met Coal

Ramaco Resources, Inc. - Class A Common Stock

Ramaco Resources

Ramaco Resources, Inc. - Class B Common Stock

Mesabi Tr

ArcelorMittal

Nucor

POSCO HOLDINGS INC. American Depositary Shares (Each representing 1/4th of a share of Common Stock)

POSCO Holdings

Radius Recycling, Inc. - Class A Common Stock

Radius Recycling

Reliance

Ryerson Holding

Companhia Siderurgica Nacional S.A. Common Stock

Companhia Siderurgica

Steel Dynamics

SunCoke Energy

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Comments

Metallus

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL